![](https://impilo.se/wp-content/uploads/2024/03/rawpixel-600792-unsplash-1-q2advdqgxiwxoh4qgq6q63s82poshrqvkzbs218dsg-340x260.webp)
Helsinn and Immedica enter exclusive partnership for commercialization of cancer supportive care products in core European markets
Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of over forty years of commercial execution and a strong focus in oncology and rare diseases, and Immedica Pharma AB, a pharmaceutical company focused on commercialisation of rare and specialty care products, today announce that the companies have entered an exclusive long-term license and distribution agreement for the commercialisation of two cancer supportive care products indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV) in core European markets : AKYNZEO® (Netupitant-Palonosetron fixed combination) and ALOXI® (Palonosetron). Under the licence and distribution agreement Immedica will commercialise AKYNZEO® in Portugal, Spain, France, Switzerland, the Netherlands, Belgium, Luxembourg and Liechtenstein, ALOXI® in Switzerland, Belgium, Liechtenstein.
Read moreNews
![](https://impilo.se/wp-content/uploads/2024/09/MiniGo_600x337_130324-315x300.png)
Impilo acquires Qufora in partnership with existing shareholders
Impilo is now the majority shareholder in the Danish medtech company Qufora, which produces clinical aids for patients with chronic bowel conditions. This partnership will enable Qufora to accelerate its international expansion.
![](https://impilo.se/wp-content/uploads/2024/04/ana-francisconi-1436548-unsplash-315x500.jpg)
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
![](https://impilo.se/wp-content/uploads/2024/02/cris-trung-3wK7RLRAAkA-unsplash_aviapharma_landingpage-qj7uiwo7cyjal8ag8kydvsn338wmo96z2gi19upjgw.jpeg-315x300.webp)
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.